ML
Therapeutic Areas
Virbac SA Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Feliscratch | Feline Behavior (Scratching) | Approved |
| Iverhart / Virbamec | Canine Heartworm & Intestinal Parasites | Approved |
| Cytopoint (lokivetmab) | Canine Atopic Dermatitis | Approved |
| Endovac-Porci | Porcine Respiratory Disease Complex | Approved |
| Hipraviar S.H.A.P. | Avian Influenza (Poultry) | Approved |
| Sealed Skin Support | Dermatological Support (Dog/Cat) | Approved |
| Osphos (clodronate) | Equine Lameness (Navicular Syndrome/Bone Spavin) | Approved |
| Next-generation Parasiticides | Parasite Control (Companion Animals) | R&D |
Leadership Team at Virbac SA
SH
Sébastien Huron
Chief Executive Officer (CEO)
ÉT
Éric Thébault
Deputy CEO
GD
Gilles de la Bassetière
Chief Financial Officer (CFO)
JG
Jean-Luc Ganssien
Executive Vice President, Industrial Operations
PD
Philippe Dulac
Executive Vice President, Research & Development
LL
Loïc Lemeunier
Executive Vice President, Commercial Operations - Companion Animals
FD
François de Ricolfis
Executive Vice President, Commercial Operations - Livestock
PD
Pierre-Richard Dick
Founder and Honorary President